Actionable gene-based classification toward precision medicine in gastric cancer

[1]  Pablo Cingolani,et al.  Clinical application of a cancer genomic profiling assay to guide precision medicine decisions , 2017, Personalized medicine.

[2]  C. Yau,et al.  Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. , 2017, Gastroenterology.

[3]  J. Ajani,et al.  Global chemotherapy development for gastric cancer , 2017, Gastric Cancer.

[4]  Shujiro Okuda,et al.  Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine , 2016, Genome Medicine.

[5]  Peter Horak,et al.  Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls , 2016, ESMO Open.

[6]  Y. Bang,et al.  gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study , 2016 .

[7]  C. Kelly,et al.  The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. , 2016, Journal of gastrointestinal oncology.

[8]  N. Tsuchida,et al.  Kirsten Ras* oncogene: Significance of its discovery in human cancer research , 2016, Oncotarget.

[9]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[10]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[11]  S. Hahn,et al.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. , 2016, The Lancet. Oncology.

[12]  T. Ushijima,et al.  Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[14]  Serena Nik-Zainal,et al.  A mutational signature in gastric cancer suggests therapeutic strategies , 2015, Nature Communications.

[15]  S. Swain,et al.  Does CDKN2A loss predict palbociclib benefit? , 2015, Current oncology.

[16]  E. Perez,et al.  Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Joon-Oh Park,et al.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jingwen Zhang,et al.  Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance , 2015, Scientific Reports.

[19]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[21]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[23]  Kyoung-Mee Kim,et al.  The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer , 2015, Scientific Reports.

[24]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[25]  Wei Zhang,et al.  Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy , 2015, Proceedings of the National Academy of Sciences.

[26]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[27]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[29]  S. Fox,et al.  Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.

[30]  Shibing Deng,et al.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.

[31]  Atsushi Tanaka,et al.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.

[32]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[33]  Yun Sung Cho,et al.  Genomic profile analysis of diffuse-type gastric cancers , 2014, Genome Biology.

[34]  H. Katagiri,et al.  KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas , 2013, International journal of molecular sciences.

[35]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[36]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[37]  Wendy Winckler,et al.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.

[38]  B. Hennessy,et al.  Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Heng Li,et al.  Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly , 2012, Bioinform..

[40]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[41]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[42]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[43]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[44]  Guy N. Brock,et al.  clValid , an R package for cluster validation , 2008 .

[45]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[46]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[47]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[48]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.